McBride D, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Roth N, Weller K, Maurer M, Koenders J, Knulst AC, Elberink JN, Halliday A, Alexopoulos ST, Nakonechna A, Abouzakouk M, Sweeney C, Radder C, Wolin D, Hollis K, Tian H, Balp MM, Grattan C. First real-world study assessing health utility values for chronic spontaneous/idiopathic urticaria using the EQ-5D. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

OBJECTIVES: Although chronic spontaneous (idiopathic) urticaria (CSU/CIU) is not life threatening, it can significantly impact a patient's life when not adequately controlled by medication. Patients experience disturbing itch, intermittent pain, lack of sleep, occupational disabilities and social isolation with high impact on health-related quality of life (HRQoL). However, data on the humanistic burden associated with symptomatic persistent CSU/CIU is scarce. Here we present data on utility values from the first international burden of illness study in CSU/CIU.

METHODS: ASSURE-CSU is an observational, non-interventional study which included a 1-year retrospective medical record abstraction and a cross-sectional patient-reported outcomes survey. Adult CSU/CIU patients aged greater than or equal to 18 years with disease persisting for greater than 12 months despite treatment were assessed. Utility values and domain scores from EQ-5D-3L were described for Canada, Germany, UK and the Netherlands.

RESULTS: A total of 88, 98, 79 and 99 patients completed the patient survey which included the EQ-5D-3L in Canada, Germany, UK and the Netherlands, respectively. The mean (SD) EQ-5D-3L utility score was 0.71 (0.30) for Canada; 0.71 (0.25) for Germany; 0.72 (0.31) for UK and 0.76 (0.27) for the Netherlands. Among the different dimensions of EQ-5D-3L, pain/discomfort was the most affected with 62.0%, 70.5%, 61.5% and 56.6% of patients reporting moderate to extreme problems, respectively. The second most affected dimension was anxiety/depression for Canada, Germany and UK with 41.8%, 51.6% and 45.6% of patients reporting moderate to extreme problems, respectively. For the Netherlands, usual activities (44.4%) was the second most affected dimension. Impact across all dimensions increased with disease severity and correspondingly utility values decreased.

CONCLUSIONS: This is the first real-world study to assess utility values in CSU/CIU using EQ-5D. Utility scores were similar among the countries and ranged from 0.71 to 0.76, suggesting that CSU/CIU have significant impact on the patients' health status. Pain/discomfort was the most affected dimension across countries.